Bio-Rad Laboratories Inc. CI A (BIO) News
Filter BIO News Items
BIO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BIO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest BIO News From Around the Web
Below are the latest news stories about BIO-RAD LABORATORIES INC that investors may wish to consider to help them evaluate BIO as an investment opportunity.
Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic TestsST. LOUIS & HERCULES, Calif., January 08, 2025--Geneoscopy raises $105 million in Series C funding round, led by Bio-Rad Laboratories |
Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare ConferenceHERCULES, Calif., January 02, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz, Chief Operating Officer Jon DiVincenzo, and Chief Financial Officer Roop K. Lakkaraju will host one-on-one meetings with analysts and investors during J.P. Morgan's 43rd Annual Healthcare Conference in San Francisco, CA, January 13-16, 2025. |
At US$331, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?Bio-Rad Laboratories, Inc. ( NYSE:BIO ), might not be a large cap stock, but it received a lot of attention from a... |
Bio-Rad (BIO) Down 5.5% Since Last Earnings Report: Can It Rebound?Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)Key Insights Using the 2 Stage Free Cash Flow to Equity, Bio-Rad Laboratories fair value estimate is US$323 Current... |
Bio-Rad Laboratories, Inc. (BIO): A Bull Case TheoryWe came across a bullish thesis on Bio-Rad Laboratories, Inc. (BIO) on Substack by Stock Analysis Compilation. In this article, we will summarize the bulls’ thesis on BIO. Bio-Rad Laboratories, Inc. (BIO)’s share was trading at $323.69 as of Nov 20th. BIO’s forward P/E was 28.49 according to Yahoo Finance. Bio-Rad Laboratories (BIO) is a leading manufacturer […] |
Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare ConferenceHERCULES, Calif., November 21, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will host one-on-one meetings with analysts and investors during Citi's 2024 Global Healthcare Conference in Miami, FL, December 3-5, 2024. |
What Makes Bio-Rad Laboratories (BIO) an Attractive Opportunity?Ariel Investments, an investment management company, released its “Ariel Focus Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. Due to the economy’s resilience and forecasters’ expectations of a soft landing, all major U.S. indices enjoyed gains in the third quarter. In the third quarter, the fund returned +10.61%, outperforming the […] |
Interpreting Bio-Rad (BIO) International Revenue TrendsExamine the evolution of Bio-Rad's (BIO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects. |
Bio-Rad Laboratories, Inc. (NYSE:BIO) Just Released Its Third-Quarter Results And Analysts Are Updating Their EstimatesShareholders of Bio-Rad Laboratories, Inc. ( NYSE:BIO ) will be pleased this week, given that the stock price is up 15... |